Detalhe da pesquisa
1.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Haematologica;
2021 08 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34382384
2.
Therapeutic Advances in the Management of Smoldering Myeloma.
Am J Ther;
27(2): e194-e203, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31842112
3.
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.
BMC Cancer;
19(1): 1238, 2019 12 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31862002
4.
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.
BMC Cancer;
18(1): 1152, 2018 Nov 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30463534
5.
Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma.
Occup Environ Med;
75(11): 798-806, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30121582
6.
Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.
Br J Haematol;
174(4): 536-40, 2016 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27172326
7.
Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.
Br J Haematol;
175(1): 87-101, 2016 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27330041
8.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Haematologica;
106(12): 3215-3218, 2021 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34847659
9.
Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Am J Hematol;
96(9): E341-E344, 2021 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34050985
10.
Drug Combinations with Transplantation for Myeloma.
N Engl J Med;
377(1): 91-2, 2017 07 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28679086
11.
RARα2 expression confers myeloma stem cell features.
Blood;
122(8): 1437-47, 2013 Aug 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23847194
12.
Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients.
J Clin Apher;
30(1): 1-7, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24941931
13.
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Biol Blood Marrow Transplant;
20(12): 1949-57, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25139216
14.
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Blood Adv;
8(3): 703-707, 2024 02 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38052037
15.
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
J Clin Invest;
134(1)2024 Jan 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37883186
16.
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx.
Res Sq;
2024 May 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38766009
17.
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Cancers (Basel);
16(6)2024 Mar 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38539451
18.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Nat Commun;
15(1): 615, 2024 Jan 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38242888
19.
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
Blood Adv;
7(21): 6676-6684, 2023 11 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37756524
20.
A gene signature can predict risk of MGUS progressing to multiple myeloma.
J Hematol Oncol;
16(1): 70, 2023 06 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37386588